Real World Experience of Bezlotoxumab for Prevention of Recurrent C. Difficile Infection: A Single-Arm Multicenter Pilot Study in Office Infusion Centers
Timothy E. Ritter – Texas Digestive Disease Consultants, Southlake, TX
Richard L. Hengel – Atlanta ID Group, Atlanta, GA; Piedmont Healthcare, Atlanta, GA
Curtis J. Fitzsimmons – Plaza Infectious Disease, Kansas City, MO; University of Missouri-Kansas City, MO
Kevin Garey – University of Houston College of Pharmacy, Houston, TX
Lucinda J. Van Anglen – Healix Infusion Therapy, Sugar Land, TX
Claudia P. Schroeder – Healix Infusion Therapy, Sugar Land, TX
Stephen W. Marcella – Center for Observational and Real World Evidence, Merck & Co., Inc., Rahway, NJ, USA
John J. Hawkshead – Center for Observational and Real World Evidence, Merck & Co., Inc., Rahway, NJ, USA